New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
10:25 EDTCVD, CVD, EBS, EBS, CI, CI, BSX, BSX, BMY, BMY, AMGN, AMGN, ABT, ABT, HNT, HNT, SHPG, SHPG, REGN, REGN, PDCO, PDCO, VRTX, VRTXJPMorgan to host a conference
32nd Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 14 at 10:30 am; not all presentations may be webcasted. Webcast Link
News For CVD;PDCO;REGN;SHPG;HNT;ABT;AMGN;BMY;BSX;CI;EBS;VRTX From The Last 14 Days
Check below for free stories on CVD;PDCO;REGN;SHPG;HNT;ABT;AMGN;BMY;BSX;CI;EBS;VRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 16, 2014
05:20 EDTREGNRegeneron initiated with a Buy at Canaccord
Subscribe for More Information
April 15, 2014
16:47 EDTBSXBoston Scientific announces FDA approval for defibrillators
Subscribe for More Information
15:19 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:14 EDTABTEarnings Preview: Abbott's established pharmaceuticals sales in focus
Subscribe for More Information
11:53 EDTBSXVascular Solutions: Injunction against Boston Scientific's Guidezilla vacated
Subscribe for More Information
09:23 EDTBSXBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
08:23 EDTBMYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTBMYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:22 EDTSHPGNovartis to Shire said to mull offers for ThromboGenics, Bloomberg says
Subscribe for More Information
06:32 EDTCI, BMY, HNTPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
10:02 EDTBSXOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
09:05 EDTABTAbbott announces FDA clearance for test to diagnose diabetes
Subscribe for More Information
08:15 EDTBMYBristol-Myers submits NDA for Reyataz-cobicistat combo for HIV-1
Bristol-Myers Squibb (BMY) announced the submission of a new drug application, or NDA, on April 4 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb is seeking approval of the fixed-dose combination tablet for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is being developed by Gilead Sciences (GILD). Under the terms of a previously announced agreement, Bristol-Myers Squibb and its affiliates are responsible for the formulation, manufacturing, registration, distribution and commercialization of the atazanavir sulfate and cobicistat fixed-dose combination product worldwide. Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.
06:44 EDTBSXBoston Scientific upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded Boston Scientific to Buy from Neutral. The firm upgraded shares given increased confidence in the pipeline, opportunities to increase margin, valuation, and expectations the FDA will approve the LAA product this year. Price target raised to $16.
06:18 EDTBSXBoston Scientific upgraded to Buy from Neutral at BofA/Merrill
Price target is $16.
April 10, 2014
18:34 EDTBSXBoston Scientific enrolls first patient in registry for evaluating Vercise DBS
Subscribe for More Information
08:34 EDTABTAbbott completes enrollment of Absorb clinical trials in U.S., Japan and China
Subscribe for More Information
07:04 EDTBMYBristol-Myers presents Phase III data on all-oral Daclatasvir and Asunaprevir
Subscribe for More Information
April 9, 2014
11:43 EDTABT, BMYGilead defended by analysts after recent pullback
Subscribe for More Information
07:23 EDTBMYEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use